Jan 16, 2024 · The multicenter, double-blind, randomized, placebo-controlled Phase 2 trial will evaluate the efficacy and safety of ilofotase alfa as a ...
Missing: Farma | Show results with:Farma
Mar 9, 2018 · Based on strong results from Phase II trials with bovine Alkaline Phosphatase in AKI and UC, AM‐Pharma has developed an innovative recombinant ...
Missing: Farma | Show results with:Farma
People also ask
What is recAP AM Pharma?
What is ilofotase alfa?
Oct 20, 2022 · Ilofotase alfa failed to improve kidney function in the first seven days, causing the phase 2 to miss its primary endpoint and Pfizer to walk ...
Missing: Farma | Show results with:Farma
Mar 9, 2018 · CEO at AgomAb Therapeutics ... It is with great pleasure to announce that recAP significantly reduced mortality in our phase IIb study. We must ...
Missing: Farma | Show results with:Farma
Jan 16, 2024 · Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery.
The nomination is based on AM-Pharma's two-part adaptive Phase II clinical trial design of recAP in patients with sepsis-associated Acute Kidney Injury.
Missing: Farma | Show results with:Farma
Sep 26, 2023 · The planned double-blind, randomized, placebo-controlled Phase 2 clinical trial will evaluate the safety and efficacy of ilofotase alfa in 150 ...
Missing: Farma | Show results with:Farma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI). The company ...
Missing: Farma | Show results with:Farma
May 22, 2017 · The trial, titled A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI (STOP-AKI), completed ...
Missing: Farma | Show results with:Farma
No information is available for this page. · Learn why